MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2024 International Congress

    Lumbar Punctures in Parkinson’s Research

    A. Navangul, H. Matthews, M. Bartlett, H. Groves, S. Stott, A. Noyce (London, United Kingdom)

    Objective: This study aims to explore patient perspectives on lumbar punctures for cerebrospinal fluid (CSF) analysis in Parkinson’s disease (PD) research, with the objective of…
  • 2024 International Congress

    Differential Symptom Cluster Responses and Predictors to Repetitive Transcranial Magnetic Stimulation Treatment in Parkinson’s Disease:A Retrospective Study

    J. Sun, P. Hu (hefei, China)

    Objective: This study aimed to investigate the related factors for the response to rTMS in PD patients. Background: Repetitive transcranial magnetic stimulation (rTMS) is an…
  • 2024 International Congress

    Effect of Istradefylline on Motor and Non-motor Symptoms in Patients with Parkinson’s Disease: the ISTRA ADJUST PD Randomized, Controlled Study

    H. Nagayama, T. Hatano, R. Sengoku, N. Yanagisawa, O. Kano (Tokyo, Japan)

    Objective: To examine the effects of istradefylline on motor and non-motor symptoms in Parkinson’s disease (PD) patients with wearing-off phenomena. Background: Previous results [1,2] of…
  • 2024 International Congress

    Impact of IPX203 on Parkinson’s patients’ motor states upon awakening: analysis of patient diary data

    S. Isaacson, H. Fernandez, C. Kilbane, G. Banisadr, A. Pitman, S. Fisher, R. D'Souza (Boca Raton, USA)

    Objective: To evaluate “On” upon awakening in Parkinson’s disease patients taking IPX203 in the RISE-PD phase 3 clinical trial. Background: IPX203 is a novel extended-release,…
  • 2024 International Congress

    Long-term Safety and Efficacy for Motor Fluctuations and Quality of Life With Foslevodopa/Foscarbidopa in Patients With Advanced Parkinson’s Disease: Interim Results From an Ongoing Open Label Extension

    F. Bergquist, J. Aldred, C. Carroll, E. Danielsen, M. Facheris, R. Gupta, A. Jeong, A. Spiegel, V. Fung (Mölndal, Sweden)

    Objective: Evaluate long-term motor symptom control and improvement in quality of life (QoL) with foslevodopa/foscarbidopa (LDp/CDp) compared with baseline (BL) values from the parent study…
  • 2024 International Congress

    Parkinson’s Progression Markers Initiative (PPMI): Investigating Biomarker Driven PD Progression

    B. Mcmahon, A. Siderowf, T. Simuni, C. Tanner, B. Mollenhauer, C. Coffey, D. Galasko, K. Poston, L. Chahine, R. Dobkin, T. Foroud, K. Kieburtz, D. Weintraub, K. Merchant, M. Frasier, T. Sherer, S. Chowdury, E. Brown, R. Alcalay, A. Videnovic, K. Fabrizio, E. Flagg, C. Stanley, K. Marek (Baltimore, USA)

    Objective: PPMI is a longitudinal, observational study enrolling PD participants, individuals at risk for PD, and healthy controls (HCs). The study investigates clinical, imaging, genetic…
  • 2024 International Congress

    Non-interventional phase 0 study for the collection of biospecimens from patients with Parkinson’s Disease (PD) to support the development of a diagnostic classifier for LRRK2-driven PD

    L. Desnoyers, S. Dheerendra, C. Wong, T. Dang, S. Esmaeeli, M. van Derbrug, M. Nalls, A. Ellenbogen, S. Jackson (South San Francisco, USA)

    Objective: Measure LRRK2 pathway activity in Parkinson’s Disease patients stratified using a genetic predictive classifier model. Background: Extensive research has shown that overactivation of the…
  • 2024 International Congress

    Improvement in Uninterrupted Good ON Time and Reduction in OFF Periods with CSAI Treatment

    D. Kremens, R. Hauser, A. Formella, M. Joshi, M. Grall (Philadelphia, USA)

    Objective: Evaluate the effect of continuous subcutaneous apomorphine infusion (CSAI) on daily periods of OFF time and Good ON time (ON without troublesome dyskinesia) in…
  • 2024 International Congress

    Blautia argi ameliorates the motor impairment of 6-Hydroxydopamine hydrochloride-induced Parkinson’s disease rat model

    G. Tian, R. Zhou, J. Lu, W. Shi, R. Li, X. Guo (Xi'an, China)

    Objective: To evaluate the potential protective effects of Blautia argi on a 6-Hydroxydopamine (6-OHDA)-induced rat model of Parkinson's disease (PD). Background: PD is a common…
  • 2024 International Congress

    Continuous Dopaminergic Stimulation-based Levodopa Treatment in Early to Mid-stage Parkinson’s Disease Patients: A Systematic Review and Meta-analysis

    R. Tang, R. Sun, S. Zhang, L. Chen (Shanghai, China)

    Objective: To compare the clinical effectiveness between continuous dopaminergic stimulation (CDS)-based and intermittent levodopa (IL) treatment in patients with early to mid-stage Parkinson’s disease (PD).…
  • « Previous Page
  • 1
  • …
  • 86
  • 87
  • 88
  • 89
  • 90
  • …
  • 338
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Survey-Based study of marijuana used in Parkinson’s Disease patients
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Life expectancy with and without Parkinson’s disease in the general population
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley